Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (HALB) is an innovative biopharmaceutical company developing targeted therapies for PTSD, traumatic brain injury, and related mental health conditions through patented drug formulations and wearable monitoring technologies. This news hub provides investors and researchers with timely updates on the company's clinical trials, intellectual property developments, and strategic partnerships.
Access authoritative information about HALB's progress in mental health treatment innovation, including updates on its LDN+ and Tri-Ax nasal spray therapies. The repository consolidates press releases related to CRADA clinical trials, technology integrations with partners like Athena GTX, and patent filings that underpin the company's valuation.
Key content categories include regulatory milestones, research collaborations with military healthcare providers, and advancements in combined pharmaceutical/digital health solutions. All materials maintain compliance with OTC Market disclosure standards while emphasizing HALB's unique position at the intersection of biopharma and wearable diagnostics.
Bookmark this page for streamlined tracking of HALB's progress in addressing critical mental health challenges through evidence-based therapeutic innovation. Check regularly for verified updates that reflect the company's commitment to advancing both patient care and shareholder value.
Halberd Corporation (OTC PINK:HALB) has initiated groundbreaking experiments aimed at eradicating key components of Alzheimer's Disease. The company intends to target three critical antigens linked to neurofibrillary tangles using a patented extracorporeal treatment process, which operates directly on cerebrospinal fluid. Halberd has secured antibodies against Tau, Phosphorylated Tau, and Beta Amyloid and is in the process of conjoining metallic nanoparticles to enhance their efficacy. CEO William A. Hartman expressed confidence in their methodology, emphasizing its potential to transform Alzheimer's treatment.
Halberd Corporation (OTC PINK:HALB) has announced the development of two new neutralizing antibodies against the SARS-CoV-2 Spike Protein, exhibiting greater binding affinity compared to previous antibodies. These antibodies target different regions of the Spike protein, enhancing the potential effectiveness of treatments when combined with existing antibody cocktails. The company is progressing with its patented extracorporeal treatment process aimed at eradicating disease antigens. Step 4 of their development roadmap is currently underway, focusing on effectiveness against SARS-CoV-2 and E. coli bacteria.
Halberd Corporation (OTC PINK:HALB) has filed a U.S. provisional patent application for an innovative technology aimed at treating and detecting SARS-CoV-2 using antibody-conjugated nanoparticles. Developed through research at Arizona State University, this technology allows for the elimination of viruses via radio waves and enhances the ability to detect viral load in patients. The CEO emphasized the broader application of this method for various infections, aiming for wide-ranging treatment capabilities.
Halberd Corporation (OTC PINK:HALB) announced a significant breakthrough in pathogen eradication. The company successfully conjugated gold-coated iron nanoparticles with E. coli antibodies, a vital step in eliminating bacteria from bodily fluids using radio frequency and laser energy. E. coli is a major cause of spinal infections and blood sepsis, responsible for nearly 250,000 deaths in the U.S. annually. The research, led by Dr. Shawn Q. Chen, shows promise for treating antibiotic-resistant bacteria and aims to reduce side effects compared to conventional therapies.
Halberd Corporation (OTC PINK:HALB) was recently featured in a MarketWatch article alongside major biotech firms discussing innovative COVID-19 treatments. The company utilizes radio waves and laser energy to eliminate the SARS-CoV-2 virus from body fluids, presenting a unique offering in the market. CEO William A. Hartman expressed pride in the recognition and emphasized Halberd's potential for broader medical applications beyond COVID-19. The firm holds exclusive rights to several patent-pending treatments for COVID-19 and other related conditions.
Halberd Corporation (OTC PINK:HALB) has been highlighted as a potential breakout stock in investor publications, with expectations for its share price to exceed $0.06. The company, which holds multiple patents related to treating diseases via innovative methods using Radio Frequency and lasers, recently appointed Dr. Mitchell S. Felder as Chief Technical Officer. Halberd aims to advance its extracorporeal treatment processes, promising to revolutionize medical treatments by eradicating diseases without the harmful side effects of traditional medications. Upcoming proof-of-concept tests are anticipated to yield significant results.
Halberd Corporation has appointed Dr. Mitchell S. Felder as Chief Technical Officer, succeeding Dr. Patricio Reyes, who will continue as a consultant. Dr. Felder, a Board-Certified Neurologist with numerous patents related to disease eradication, will oversee testing in radio frequency and laser technologies. This transition is expected to enhance R&D efforts at Youngstown State University, focusing on eradicating E. coli bacteria as a precursor to tackling other pathogens, including COVID-19. Halberd holds several patents and applications relevant to its initiatives.
Halberd Corporation (OTC PINK:HALB) has filed a PCT application for its invention titled Treating and Curing Covid-19 Infection Utilizing a Laser. This international application enables patent protection across over 150 countries. CEO William A. Hartman stated this technology could revolutionize Covid-19 treatment through laser ablation methodology. The company is also initiating laser experimentation at Youngstown State University and holds exclusive rights to several patents and applications related to Covid-19 treatments, enhancing its position in the medical technology sector.
Halberd Corporation (OTC PINK:HALB) announced that its two patent-pending monoclonal antibodies have shown significant effectiveness against three SARS-CoV-2 mutations: Q498Y, P499T, and Q493K. Principal researcher Dr. Shawn Chen emphasized the strong neutralizing capabilities of these antibodies. Plans for mouse testing are underway to confirm laboratory results. CEO William Hartman expressed optimism about these antibodies potentially addressing key COVID-19 variants. Halberd holds various patent applications related to COVID-19 treatments and is in full compliance with OTC Market requirements.
Halberd Corporation (OTC PINK:HALB) has announced Dr. William G. Sturrus from Youngstown State University (YSU) will lead research in Radio Frequency (RF) technology aimed at eradicating infectious diseases. With over 30 years of experience, Dr. Sturrus's team, comprising faculty and students, is set to begin experiments shortly. This collaboration aims to prove that diseases can be eliminated from bodily fluids using RF waves combined with Halberd's patented processes. The technology promises minimal side effects compared to traditional treatments, paving the way for revolutionary medical advancements.
FAQ
What is the current stock price of Halberd (HALB)?
What is the market cap of Halberd (HALB)?
